We previously found that HER2 amplified BT474 breast cancer persister cells have a broadly disabled antioxidant program with diminished expression of NRF2 target genes including system xC− components and decreased levels of GSH and NADPH(3). This evidence concerns the gene ERBB2 and breast carcinoma.